Extension clause and over-allotment option fully exercised. Definitive terms :
Subscription price: €7.20 per share ; Number of new shares issued: 1,634,718
(after full exercise of the extension clause and the over-allotment option)
Gross proceeds from the offering: €11,769,970.

Risk factors
IPSOGEN draws the public's attention to the risk factors described in the prospectus.
Luminy, 10 June, 2008 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and marketing of molecular diagnostic tests for cancer, announces the success of the offer that ended on 9 June 2008 and its listing on Alternext. Demand exceeded supply. The extension clause was fully exercised and the over-allotment immediately exercised, bringing the number of shares issued to the maximum level of 1,634,718. The definitive price was set at €7.20 per share. Gross proceeds from the issue amounted to €11,769,970, including the issue premium.
These funds will be used primarily for the development of commercial operations and further regulatory registrations of molecular diagnostics products for blood and breast cancer. Settlement-delivery of the shares offered will take place on 13 June 2008 and the shares will be listed
for continuous trading on Alternext from 16 June 2008 under ISIN code FR0010626028.
The Initial Public Offering breaks down as follows:
- Global Placement: 1,421,494 shares (87% of the total number of shares offered);
- Open Price Offer: 213,224 shares (13% of the total number of shares offered). More than 736 private investors subscribed to the offer.
The free float represents 35% of share capital and voting rights (on a fully diluted basis). The initial public offering was led by Bryan, Garnier & Co. Limited as sole Lead Manager, Bookrunner and Listing Sponsor.
IPSOGEN would like to thank all its shareholders, employees and partners, who helped to ensure the success of the offering.

Availability of the prospectus
Copies of the prospectus are available free of charge from Ipsogen's head office, from Bryan, Garnier & Co. Limited, on the Autorité des Marchés Financiers website (http://www.amf-france.org/) and on the Ipsogen website (http://www.ipsogen.com/).

About Ipsogen
Ipsogen is a cancer profiler that develops and markets molecular diagnostic assays designed to map diseases and guide clinicians’ and patients’ decisions along the complex therapeutic path. With more than 60 products already used routinely in more than 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that has been inaccessible until now. Ipsogen is also a partner of choice for  biopharmaceutical companies committed to revolutionary companion diagnostics. Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highlyskilled multidisciplinary team in France and the US, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards
that have a significant impact on patients, medical professionals and society in general. Ipsogen employed 40 people as of April 30,2008. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, Connecticut, USA.

IPSOGEN
Vincent Fert
Chief Executive Officer
Stanislas Piot
Chief Financial Officer
Tel: +33 (0)4 91 29 30 90
Cet e-mail est protégé contre les robots collecteurs de mails, votre navigateur doit accepter le Javascript pour le voir
Bryan, Garnier & Co. Ltd
Listing Sponsor
Christian Finan
Tel : +33 (0)1.56.68.75.20
Cet e-mail est protégé contre les robots collecteurs de mails, votre navigateur doit accepter le Javascript pour le voir
NewCap. Financial Communication & Investor Relations
Axelle Vuillermet / Pierre Laurent
Tel: +33 (0)1 44 71 94 94
Cet e-mail est protégé contre les robots collecteurs de mails, votre navigateur doit accepter le Javascript pour le voir

This press release, and the information contained within it, is not an offer to sell or a solicitation to buy or subscribe to IPSOGEN shares in any country.). IPSOGEN shares have not been and will not be registered in accordance with the United States Securities Act of 1933, as amended (the “Securities Act of 1933”) provided that such shares have been registered with the U.S Securities and Exchange Commission or have benefited from an exemption from registration. . IPSOGEN does not intend to register IPSOGEN shares in accordance with the Securities Act of 1933 or to offer these shares for
sale in the United States of America.